GO
Loading...

Actavis Inc

More

  • April 17- Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December. "helps them to get through 2014 with a lot less competition," Morningstar analyst Damien Conover said.

  • NEW YORK, April 14- After years of responding to shareholder calls for stock buybacks and dividends, major American companies are hearing a different demand from investors: buy growth.

  • WASHINGTON, March 28- The U.S. Federal Trade Commission seeks a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired, an FTC official told a legal conference on Friday.

  • A string of mega deals drives global M&A recovery in Q1 Thursday, 27 Mar 2014 | 8:00 PM ET

    *Morgan Stanley tops global rankings. LONDON, March 28- A string of large transactions drove the value of global mergers and acquisitions activity up by 54 percent in the first quarter compared to the same period last year, reflecting greater deal-making confidence among chief executives.

  • In the short term, that is expected to benefit larger global competitors, such as Teva Pharmaceutical Industries Ltd, Actavis Plc and Mylan Inc, which will be called upon to supply drugs no longer available from some of their rivals in India, they said.

  • Feb 27- Valeant Pharmaceuticals International Inc sees close to 50 opportunities for mergers or acquisitions, its chief executive said on Thursday, as it aims to become one of the world's five biggest pharmaceutical companies.

  • NEW YORK, Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal payments business.

  • Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal division.

  • Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal division. Marc Andreessen and Scott Cook, both long-term eBay board members, bore the brunt of Icahn's conflict allegations.

  • Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.

  • *Forest Labs shares soar; Actavis agrees to buy company. NEW YORK, Feb 18- The S&P 500 and Nasdaq rose on Tuesday, following Wall Street's biggest weekly gain of the year, as merger activity increased confidence that there is value in the stock market even as the benchmark index nears a record high.

  • *Forest Labs shares jump, Actavis to purchase. NEW YORK, Feb 18- U.S. stocks edged up on Tuesday, following Wall Street's biggest gain of the year, as merger activity boosted confidence there is still value in the market even as the S&P 500 nears a record high.

  • *Forest Labs surges after Actavis confirms acquisition. "Much of the recent concern over the health of the U.S. economy has been explained at the hands of the weather," said Andrew Wilkinson, chief market analyst at Interactive Brokers LLC in Greenwich, Connecticut.

  • *Forest Labs surges after Actavis confirms acquisition. NEW YORK, Feb 18- U.S. stocks were little changed on Tuesday after Wall Street's biggest gain of the year as disappointing economic reports weighed on investor sentiment.

  • Feb 18- Generic drugmaker Actavis Plc said on Tuesday it would buy Forest Laboratories Inc for about $25 billion in cash and stock, expanding its portfolio of specialty pharmaceuticals for neurological and other disorders. Actavis said it would pay the equivalent of $89.48 per share, representing a premium of 25 percent to Forest's closing price on Friday.

  • *Forest Labs surges after Actavis confirms acquisition. *Shares of Forest Laboratories Inc rocketed more than 35 percent in premarket trading after Actavis said it would acquire the specialty pharmaceuticals company in a massive cash and stock deal valued at about $25 billion.

  • Feb 18- Actavis Plc is in advanced talks to acquire rival drug maker Forest Laboratories Inc in a deal that could value Forest at up to $25 billion, the Wall Street Journal reported citing people familiar with the matter. Actavis competes with larger drugmakers such as Teva Pharmaceuticals Industries Ltd and Mylan Inc..

  • Feb 17- Actavis Plc is in advanced talks to acquire rival drug maker Forest Laboratories Inc in a deal that could value Forest at up to $25 billion, the Wall Street Journal reported citing people familiar with the matter. The deal is expected to be announced as early as Tuesday, but it is possible that the talks could still fall apart, the Journal said.

  • Dec 24- Actavis Plc said U.S. health regulators denied approval to its contraceptive patch for women and asked for more data. The generic drugs maker, which received a "complete response letter" from the FDA, said it planned to work closely with the agency to address the questions.

  • Dec 24- Actavis Plc said the U.S. Food and Drug Administration denied approval to its contraceptive patch and asked for more data. The FDA questioned the differences in size/formulation between the patch used in trial and the to-be-marketed patch, in a "complete response letter" to Actavis.

Most Popular Video

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.

Thursday, 17 Apr 2014 | 5:46 PM ET

CNBC voice over talent Jim Birdsall shares the top 5 sayings from traders on "Fast Money" over the years.

Thursday, 17 Apr 2014 | 6:40 PM ET

Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.